KRAS - Wikipedia KRAS (Kirsten rat sarcoma virus oncogene homologue) is a gene that provides instructions for making a protein called K-Ras, a part of the RAS MAPK pathway The protein relays signals from outside the cell to the cell's nucleus
What’s new in KRAS mutation research? | UT MD Anderson The most frequently mutated of these oncogenic driver genes, called KRAS, is associated with some of the most fatal cancer types: lung, pancreatic and colorectal cancers
What Is KRAS and Why Is It So Hard to Target in Cancer? KRAS was difficult to target because its structure lacks the deep binding pockets most drugs need Researchers later found that KRAS switches between an “on” state, which promotes cancer, and an “off” state
KRAS Inhibitors: Targeting the Undruggable Mutation in 2026 and Beyond KRAS mutations drive approximately 20-30% of all cancers, with high prevalence in non-small cell lung cancer (NSCLC, ~30%), colorectal cancer (CRC, ~40%), and pancreatic ductal adenocarcinoma (PDAC, >90%) The most common mutation historically was G12C, but breakthroughs now extend to G12D, G12V, and multi-selective "pan-KRAS" approaches
KRAS “Cracked Open”: Karmanos Researchers Publish High-Impact Review . . . A major new review published in the high-impact Nature journal Signal Transduction and Targeted Therapy (impact factor >50) is reshaping the conversation around KRAS, one of the most historically “undruggable” oncogenes in human cancer The article, “ Targeting KRAS mutations: orchestrating cancer evolution and therapeutic challenges ,” led by researchers at the Barbara Ann Karmanos
KRAS gene: MedlinePlus Genetics The KRAS gene provides instructions for making a protein called K-Ras that is part of a signaling pathway known as the RAS MAPK pathway The protein relays signals from outside the cell to the cell's nucleus
An overview of KRAS and it’s importance in pancreatic cancer KRAS is a gene involved in cell growth regulation and mutations in KRAS, particularly common in pancreatic cancer, lead to uncontrolled cell division and are a major target for emerging cancer therapies